Faron’s Post

Check out the exciting new developments from Bio-Rad in the oncology space, including new methylation assays, IVDR certification of our BCR-ABL assay, and collaborations with leading institutions to drive clinical research. #ddPCR #PrecisionOncology #Oncology #AMPATH24

𝐍𝐞𝐰 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐀𝐥𝐞𝐫𝐭! 🚀📢 Excited to share my latest research published in 𝐂𝐞𝐥𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 on 𝐀𝐧𝐭𝐢𝐜𝐚𝐧𝐜𝐞𝐫 𝐀𝐭𝐭𝐫𝐢𝐛𝐮𝐭𝐞𝐬 𝐚𝐧𝐝 𝐌𝐮𝐥𝐭𝐢𝐟𝐚𝐜𝐞𝐭𝐞𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐈𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐋𝐚𝐞𝐭𝐫𝐢𝐥𝐞 𝐚𝐧𝐝 𝐀𝐦𝐲𝐠𝐝𝐚𝐥𝐢𝐧. For decades, these compounds have been debated as alternative cancer treatments. While clinical evidence remains inconclusive, our study explores their pharmacokinetics, biological activity, and potential therapeutic applications beyond oncology—such as their antifibrotic, anti-inflammatory, and immunoregulatory effects. However, the safety concerns, particularly related to cyanide toxicity, remain a major barrier to their clinical acceptance. Despite FDA restrictions, continued research is investigating safer activation methods for targeted cancer treatment. 𝐂𝐨𝐮𝐥𝐝 𝐭𝐡𝐢𝐬 𝐥𝐞𝐚𝐝 𝐭𝐨 𝐧𝐞𝐰 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 𝐢𝐧 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞? The potential is intriguing, but further studies are crucial. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 ⬇️ https://lnkd.in/dVxy68Ru #Cancer #CancerResearch #ClinicalTrials #Oncology Wiley

Immunophotonics, Inc. is excited to announce that a leading academic medical center that combines high-quality complex patient care with innovative scientific research received authorization to proceed with recruitment to conduct a clinical trial combining Immunophotonics’ investigational drug IP-001 with AngioDynamics' advanced ablation devices. This trial will explore the power of IP-001 following thermal ablation or irreversible electroporation (IRE) and assess the efficacy and immune response for the treatment of colorectal cancer (CRC) at different stages of the disease. Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) extend special recognition to Prof. Martijn Meijerink, Danielle Vos and Hester Scheffer for their pivotal roles in conducting a clinical trial to further evaluate the safety and efficacy of this combinational treatment to further propel the field of Interventional Immuno-Oncology™. Official Press Release:  https://lnkd.in/djTanRyV Visit us at www.immunophotonics.com   #research #interventionaloncology #immunooncology #cancer #immunotherapy #Immunophotonics #clinicaltrials #innovation #abscopalize_it #oncology #oncologyresearch #interventionalradiology #medicaloncology #trials #healthcareexcellence #biotechnology #drugdevelopment #antibody #cancerimmunity #immunophotonics #AngioDynamics

During the 2024 #AACR Annual Meeting this week, the concept of #metastasis has dramatically changed since its last plenary session 14 years ago.... David Lyden's session on "Evolution of the Genome, Microenvironment, and Host through Metastasis" reveals new insights on the importance of tumor-secreted factors and extracellular vesicles (EVPs) which can have downstream effect on different organs and can contribute towards a systemic effect. As Lyden's team discovered, EVPs as a result of a pancreatic tumor can disrupt the liver's function, increase the side effects of chemotherapy and even increase the likelihood of metastases outside the liver. Said differently, “if you have cancer going to the lung, you can’t ignore that you have a fatty liver as well.” The evolving understanding of metastasis emphasizes the need for a more comprehensive approach to cancer research and treatment. To learn more about his work and conference insights, continue reading here: https://lnkd.in/g_XJB3ed #Pharmaceutical #Biotech #Diagnoses #Medicine #Clinical #Healthcare #Lifescience #CancerResearch #CancerTreatment #CancerCells #Oncology #MedicalResearch #Healthcare #CancerAwareness #CancerBiology #InnovationInMedicine #HealthcareIndustry #CancerPrevention #CancerScience #HealthScience #MedicalCommunity #CancerEducation

🎯 Developing Efficacious Drugs with Better Combinability Join Paul Workman, Timothy A. Yap, and Jerome Mettetal at the AACR Conference on Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry (December 9–11). This important session will explore strategies to enhance the combinability of cancer therapeutics—paving the way for more effective and tolerable treatments. 📅 Save the date and register here: https://bit.ly/4gLZMYO #CancerResearch #DrugDevelopment #AACRchem24

Friday, April 12th, the #𝐅𝐃𝐀’𝐬 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐢𝐜 𝐃𝐫𝐮𝐠𝐬 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐂𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐞 𝐯𝐨𝐭𝐞𝐝 𝟏𝟐 𝐭𝐨 𝟎 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐭𝐨𝐭𝐚𝐥𝐢𝐭𝐲 𝐨𝐟 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐝𝐚𝐭𝐚 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐭𝐡𝐞 𝐮𝐬𝐞 𝐨𝐟 𝐦𝐢𝐧𝐢𝐦𝐚𝐥 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 (#𝐌𝐑𝐃) 𝐚𝐬 𝐚𝐧 𝐞𝐧𝐝 𝐩𝐨𝐢𝐧𝐭 𝐟𝐨𝐫 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐨𝐟 𝐧𝐞𝐰 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 #𝐦𝐲𝐞𝐥𝐨𝐦𝐚. Sebia’s CEO, Jean Marc Chermette touts, “This is a tremendous advance for patients with multiple myeloma, enabling investigators and biopharma companies to get much needed new promising agents made available and accessible. MRD plays a major role in the care of myeloma patients and having an analytically validated blood-based MRD assay such as M-inSight will serve a crucial need and spare having to perform for bone marrow biopsies”. #Sebia congratulates Representatives from The University of Miami’s Sylvester Comprehensive Cancer Center and the i2TEAMM who presented three independent data sets from a meta-analysis based on patient-level data from several clinical trials. The level of rigor of these analyses are superb and sets a new standard for biomarker development in oncology. ➡️ Visit https://lnkd.in/eXd5eNkT to learn more about M-inSight! #Minimalresidualdisease #Multiplemyeloma #MinSight

𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗱𝗿𝘂𝗴 𝗰𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 (𝗔𝗗𝗖𝘀) are a highly promising and relatively new class of therapies with a significant clinical impact in cancer treatment. Our latest case study, “𝗔𝗗𝗖 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘄𝗶𝘁𝗵 𝗦𝗲𝗹𝘃𝗶𝘁𝗮: 𝗧𝗿𝗮𝘀𝘁𝘂𝘇𝘂𝗺𝗮𝗯 𝗔𝗗𝗖𝘀 𝗶𝗻 𝗛𝗘𝗥𝟮 𝗣𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿” showcases our expertise in characterization of novel ADC binding properties, measuring efficacy in disease-relevant cell lines, and ensuring target specificity through a series of studies. Our findings reveal that treatment with T-Deruxtecan results in increased levels of phosphorylated histone H2AX, indicating DNA damage in a concentration-dependent manner. Discover the full findings from our scientific poster recently showcased at the Drug Discovery 2024 here: https://lnkd.in/eFk-S8Rf Stay updated on more research from Selvita by visiting our website: https://lnkd.in/ebj-PFDG #ADC #DrugDiscovery #CancerResearch #ELRIGDD #DrugDiscovery2024

I just had the pleasure of reading through the latest 3-4 Edition of 𝐎𝐧𝐤𝐨 𝐍𝐞𝐰𝐬 𝐀𝐮𝐬𝐭𝐫𝐢𝐚 over the weekend, and I couldn’t be more thrilled with the incredible content we've put together! Being a part of the Springer Medizin Österreich team that brings this publication to life is truly rewarding.📚💡 This edition is packed with insightful articles and updates on critical topics such as the management of side effects in immuno-oncology, the latest advancements in Antibody-Drug Conjugates (#ADCs), highlights from the #ASCO Congress, and important updates from the #ÖGHO (Austrian Society of Hematology & Medical Oncology). In addition to the insightful articles and updates, we also had the privilege of conducting #interviews with leading experts in the field.🔍🎙️ Our mission with 𝐎𝐧𝐤𝐨 𝐍𝐞𝐰𝐬 𝐀𝐮𝐬𝐭𝐫𝐢𝐚 is to keep healthcare professionals informed and supported with the latest 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉 findings, clinical study results, and advancements in cancer treatment. These publications are a testament to our commitment to enhancing medical knowledge and improving patient care.📈💊 #OnkoNewsAustria #Oncology #Hematology #MedicalResearch #HealthcareInnovation #Immunooncology

Predicine is excited to announce our exhibition in the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA, from September 7th-10th. Join us at booth #1420 to explore our advanced liquid biopsy solutions, centralized lab network, and decentralized CDx and kit manufacturing capabilities for global clinical trials, biomarker discovery, and CDx development. Be sure to inquire about our latest poster to learn about the significant clinical efficacy and tolerable safety profile of high-dose furmonertinib in EGFR-mutated NSCLC patients with leptomeningeal metastasis (LM).  Highlights:   • Globally harmonized liquid biopsy technology: outperforming ctDNA and cfRNA solutions with numerous clinical publications    • MRD detection: personalized and actionable MRD (PredicineBEACON™) & generalized, methylation MRD (PredicineALERT™)    • Global operations: supporting multiple national clinical trials, CDx developments and commercialization      Connect with our team to learn how our accurate, accessible, and affordable liquid biopsy solutions can support your global clinical trials, companion diagnostics (CDx) development, and commercialization efforts in the US, China, and ROW.     Schedule a meeting with us here: https://lnkd.in/gfAamv7U Learn more about Predicine: https://lnkd.in/gndzmpGH #LungCancer #NSCLC #Diagnostics #Oncology #NGS #LiquidBiopsy #MRD #ctDNA #CDx

WHY DANNY eCLINICAL RESEARCH? 📌 70% decrease in NIS start-up cycle 📌 55% reduction in investigator time 📌 5 times faster patient enrolment Curious to explore our success story with ‘Lung Cancer Real-world Evidence Secondary Use of Data: A Non-Interventional Study’? 👇